Skip to content
Clinical Trials – home
Not yet recruiting

Effect of Survodutide on Visceral Fat Reduction in Adults with Obesity: A Randomized, Double‑Blind, Placebo‑Controlled Trial

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on Obesity, a condition where excess body fat can lead to health problems. The investigational medicine being tested is Survodutide, which is given as a small injection under the skin. Participants will receive either this medication or a matching placebo, and the main goal is to determine whether the drug can lower the amount of fat stored around the internal organs, known as VAT, compared with the control.

During the 40‑week period, participants are randomly assigned to one of the two groups and receive regular injections. Throughout the study they will attend clinic visits where their weight, waist size, and other body measurements are checked, and they will undergo imaging scans using MRI—a type of picture‑taking that shows the inside of the body without surgery—to see changes in fat and muscle. Simple tests of muscle strength and physical performance, such as measuring the force of a knee extension or timing how quickly stairs are climbed, are also performed to assess any improvement in muscle function.

The research process

The trial runs in 8 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Assessments

    You will undergo initial measurements that include body weight, waist circumference, and height.

    An MRI scan will be performed to evaluate fat distribution and muscle composition.

    Tests of lower‑extremity muscle function, such as knee extension strength and stair‑climb performance, will be completed.

  2. Step 2

    Randomization

    You will be randomly assigned to receive either Survodutide 6.0 mg or a matching placebo.

    The study is double‑blind, meaning neither you nor the study staff will know which treatment you receive.

  3. Step 3

    First Injection

    You will receive a subcutaneous injection (injection under the skin) of the assigned medication.

    The dose of Survodutide is 6.0 mg per injection; the placebo contains no active substance.

  4. Step 4

    Regular Injections

    You will continue to receive the same subcutaneous injection at each scheduled study visit.

    Injections will be administered throughout the 40‑week trial period according to the study schedule.

  5. Step 5

    Ongoing Assessments

    At regular intervals you will have body weight, waist circumference, and body‑mass‑index (BMI) measured.

    Repeat MRI scans will be performed to track changes in visceral adipose tissue (VAT) and other fat depots.

    Muscle function tests, including knee extension peak force and stair‑climb time, will be repeated to assess functional changes.

  6. Step 6

    Safety Monitoring

    You will be asked about any side effects or symptoms at each visit.

    Blood samples may be taken to check laboratory values and ensure safety.

  7. Step 7

    Final Visit

    At week 40 you will undergo the final set of measurements, including MRI, body‑weight assessment, and muscle‑function testing.

    The final visit will determine the overall change from baseline in body weight and VAT.

  8. Step 8

    Study Completion

    You will be informed that the trial has ended and any remaining study procedures will be concluded.

Who can join the trial?

9 criteria

  • Be willing and able to sign a written informed consent, which means you understand the study and agree to take part.
  • Be between 18 and 65 years old at the time of the screening visit.
  • Have a Body Mass Index (BMI) of at least 30 and no more than 40 kg/m², a calculation that compares your weight to your height.
  • Have tried at least one diet to lose weight that did not work, as reported by you and confirmed by the study doctor.
  • Show no major health problems during a physical exam, normal vital signs, a normal heart test called an electrocardiogram (ECG), and normal blood test results.
  • If you are a woman who could become pregnant, you must use a very reliable form of birth control (failure rate less than 1%) starting two weeks before the first dose and continuing until eight weeks after the last dose, or you must abstain from sex if that is your usual lifestyle. Your male partner must also use a condom unless he has had a vasectomy. Because the study drug may affect oral birth‑control pills, you should switch to a non‑oral method or add a barrier method (like a condom) during the study.
  • You must be willing and able to learn how to give yourself the study injection, or have a trained person help you with the injection.
  • You must be motivated to follow all study procedures, including diet and exercise advice, completing questionnaires, and handling the medication as instructed.
  • You must have a good quality baseline MRI scan, a type of imaging test, that meets the study’s standards before randomization.

Who cannot join the trial?

34 criteria

  • Weight has changed by 5% or more in the three months before screening.
  • Pregnant, breastfeeding, planning to become pregnant during the study, or gave birth within the last six months.
  • Unstable mental health conditions that could affect participation, such as serious risk of suicide, active psychosis, or severe mania.
  • Any answer “yes” to recent suicide attempts, self‑injury, or serious suicidal thoughts on the screening questionnaire.
  • Any answer “yes” to having active suicidal thoughts with intent or a specific plan on the screening questionnaire.
  • Use of any obesity‑treating medication within three months before screening.
  • Weight‑changing medicines (like certain blood pressure drugs, antidepressants, antipsychotics, anti‑seizure medicines, antihistamines, or steroids) started within three months before screening, unless you have been on them for more than three months with stable weight.
  • Recent or planned weight‑loss surgery or devices (such as gastric bypass, gastric balloons, duodenal‑jejunal sleeve, or similar procedures), except for certain older surgeries like liposuction, hernia repair, or gallbladder removal performed more than a year ago.
  • Obesity caused by other hormone disorders (for example, Cushing syndrome) or rare genetic forms of obesity (such as melanocortin‑4‑receptor deficiency, leptin deficiency, or Prader‑Willi syndrome).
  • Blood test showing Hemoglobin A1c (average blood sugar level over several months) of 6.5% or higher.
  • Diagnosed with type 1 or type 2 diabetes, or started a diabetes‑lowering medication within three months before screening.
  • Kidney function that is very low, measured as an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², or needing dialysis.
  • Severe problems with stomach emptying, such as serious diabetic gastroparesis or blockage at the stomach outlet.
  • Uncontrolled thyroid problems (either underactive or overactive thyroid) as judged by the doctor.
  • History of pancreas inflammation (pancreatitis) or blood tests showing pancreatic enzymes (lipase or amylase) more than twice the normal upper limit.
  • High blood pressure that is not controlled (systolic ≥ 160 mmHg or diastolic ≥ 100 mmHg) at screening.
  • Recent serious heart or blood‑vessel events within three months, such as heart failure hospitalization, heart attack, unstable chest pain, stroke, or serious peripheral vascular problems.
  • Heart failure classified as very severe (New York Heart Association class IV).
  • Heart rhythm test (ECG) showing a QT interval (measure of heart’s electrical recovery) longer than 470 ms for women or 450 ms for men, or a personal/family history of long QT syndrome.
  • Liver blood tests showing very high levels of enzymes (AST or ALT) at least three times the normal limit, or total bilirubin at least 1.2 times normal (except in a harmless condition called Gilbert’s syndrome).
  • Any chronic liver disease other than fatty liver disease, such as liver cirrhosis, alcoholic liver disease, autoimmune liver disease, primary biliary cholangitis, primary sclerosing cholangitis, Wilson’s disease, or ongoing viral hepatitis.
  • Positive test for illegal drugs or for alcohol use at the screening visit.
  • Positive test for hepatitis B surface antigen, hepatitis C antibody, or HIV at screening.
  • Major surgery performed within three months before screening or planned during the study.
  • Personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN 2).
  • Blood test showing calcitonin level of 100 pg/mL (or higher), which can be a marker for certain thyroid cancers.
  • Diagnosed with cancer within the past five years, except for fully treated skin cancers (basal‑cell or squamous‑cell). Ongoing evaluation for cancer also excludes participation.
  • Blood disorders that could affect the accuracy of the Hemoglobin A1c test, such as hemolytic anemia or sickle cell disease.
  • Known or suspected allergic reaction to the study drug or related products.
  • Unlikely to follow the study rules or finish the trial, such as due to chronic alcohol or drug abuse or other reliability concerns.
  • Need to keep taking prohibited medicines that could interfere with the study’s safety or results.
  • Currently enrolled in another investigational drug or device trial, or less than 30 days (or five drug half‑lives, whichever is longer) since finishing another such trial.
  • Conditions that make MRI unsafe, such as severe claustrophobia, metal implants, pacemakers, defibrillators, artificial heart valves, or certain tattoos that could affect imaging.
  • Work as a metal worker or welder, unless the doctor is sure there are no MRI safety issues.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Survodutide is an experimental medicine that is given as a liquid that is injected just under the skin. In this study it is being tested to see if it can help people who are obese lower the amount of fat around their internal organs (visceral fat) and improve how their muscles work. Participants receive the injection regularly over 40 weeks, and researchers compare the changes in their body fat and muscle function to those who receive a placebo.

What is already known about the treatment

Survodutide - Survodutide is supplied as a sterile solution for subcutaneous injection, meaning it is a liquid that is given under the skin. It is an investigational peptide that is currently only available in clinical trials and has not yet been approved or widely reported in the medical literature. The main use being studied is for obesity, where it aims to lower visceral fat and support muscle function. It works by activating receptors that regulate appetite and energy use, classifying it as a peptide hormone analog used for weight management.

Investigated diseases

Obesity - A condition in which excess body fat accumulates to a level that may affect health. It develops when energy intake consistently exceeds energy expenditure over time. The surplus calories are stored as fat in various body compartments, including under the skin and around internal organs. As the amount of stored fat increases, body weight rises and the distribution of fat may change, often expanding the abdominal region. This gradual buildup can lead to further increases in body mass and changes in body composition.
Trial detailsLast updated 22 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-527342-44-00Protocol codeIN-FORM-01Estimated enrolment30 patientsSponsorCTC Clinical Trial Consultants AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.